🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Russell Z. Szmulewitz

University of Chicago

ORCID: 0000-0002-1444-3617
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 14 papers. Top paper: “Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide.”.

Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.183
N/A
0DataRank · unranked
2 citations

Susan Halabi, Joseph D. Schonhoft, Jun Luo, David M. Nanus, Paraskevi Giannakakou +13 more

AR-V7 and prediction of benefit with taxane therapy: Final analysis of PROPHECY.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.184
N/A
0DataRank · unranked
1 citations

Jun Luo, Monika Anand, Emmanuel S. Antonarakis, David M. Nanus, Paraskevi Giannakakou +10 more

IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002903
N/A
0DataRank · unranked
67 citations

Chihiro Morishima, Russell Z. Szmulewitz, Lauren C. Harshman, Leonard J. Appleman, Paul Monk +18 more

Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer

Cancer(2021)10.1002/cncr.33324
N/A
0DataRank · unranked
38 citations

Nancy Kwon, Jimin Wu, Connie To, Steven To, Russell Z. Szmulewitz +6 more

Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3471
N/A
0DataRank · unranked
37 citations

Susan Halabi, Joseph D. Schonhoft, Qian Yang, Jun Luo, David M. Nanus +19 more

PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3233
N/A
0DataRank · unranked
25 citations

Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore +8 more

Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics

Molecules(2023)10.3390/molecules28166041
N/A
0DataRank · unranked
14 citations

Hannah J. Zhang, R. Freifelder, Mohammed Bhuiyan, Phillip Selman, Megan Mendez +19 more

FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy (SRT) and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate/Prednisone (AAP) and Apalutamide (Apa) Post-Radical Prostatectomy (RP)

International Journal of Radiation Oncology*Biology*Physics(2023)10.1016/j.ijrobp.2023.06.401
N/A
0DataRank · unranked
3 citations

Marisa Kollmeier, Dana E. Rathkopf, Richard M. Hoffman, A. Zurita-Saavedra, Daniel E. Spratt +15 more

Phase I trial of enzalutamide (Enz) plus the glucocorticoid receptor antagonist relacorilant (Rela) for patients with metastatic castration resistant prostate cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5062
N/A
0DataRank · unranked
6 citations

Anthony V. Serritella, Walter M. Stadler, Peter H. O’Donnell, Randy F. Sweis, Russell Z. Szmulewitz +1 more

Data from Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide

(2023)10.1158/1078-0432.c.6530474.v1
N/A
0DataRank · unranked
0 citations

Susan Halabi, Joseph D. Schonhoft, Qian Yang, Jun Luo, David M. Nanus +19 more

The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3017
N/A
0DataRank · unranked
14 citations

Siyuan Guo, Joseph J. Park, David M. Nanus, Daniel J. George, Emmanuel S. Antonarakis +8 more

Catalyzing Pharmacogenomic Analysis for Informing Pain Treatment (C-PAIN): A Randomized Trial of Preemptive CYP2D6 Genotyping in Cancer Palliative Care

Journal of Pain Research(2024)10.2147/jpr.s488416
N/A
0DataRank · unranked
2 citations

Theodore Karrison, Matthew Jack, Anish Choksi, Randall W. Knoebel, Kiang-Teck J Yeo +6 more

Synthesis of DOTA-Based 43Sc Radiopharmaceuticals Using Cyclotron-Produced 43Sc as Exemplified by [43Sc]Sc-PSMA-617 for PSMA PET Imaging

Methods and Protocols(2025)10.3390/mps8030058
N/A
0DataRank · unranked
2 citations

Mohammed Bhuiyan, R. Freifelder, Hannah J. Zhang, Lucas Gonzalez, Antonino Pusateri +14 more

Impact of First‐of‐Its‐Kind Patient‐Facing Pharmacogenetics Tool on Dosing Decisions and Treatment Outcomes

Clinical Pharmacology & Therapeutics(2025)10.1002/cpt.3747
N/A
0DataRank · unranked
0 citations

Sami Elahi, Matthew Jack, John Campbell, Emily Smith, Randall W. Knoebel +11 more